Paper2887294
Camptothecin-induced in vivo topoisomerase I cleavages in the transcriptionally active tyrosine aminotransferase gene.
Stewart AF and 1 other. Cell, 1987. Cited by 147 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Camptothecin-induced in vivo topoisomerase I cleavages in the transcriptionally active tyrosine aminotransferase gene. Papers, record 2887294. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2887294
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Camptothecin-induced in vivo topoisomerase I cleavages in the transcriptionally active tyrosine aminotransferase gene.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Camptothecin | Major topic |
| DNA Damage | Major topic |
| DNA Topoisomerases, Type I | Major topic |
| DNA, Superhelical | Major topic |
| Tyrosine Transaminase | Major topic |
| Animals | |
| Cells, Cultured | |
| Cyclic AMP | |
| Genes | |
| Glucocorticoids | |
| Rats | |
| Transcription, Genetic |
Source PubMed
Cited by42
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 147 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39,802,385 | NIR Triggered Bionic Bilayer Membrane-Encapsulated Nanoparticles for Synergistic Photodynamic, Photothermal and Chemotherapy of Cervical Cancer. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/39802385 | PubMed |
| 33,260,980 | Natural Antioxidant and Anti-Inflammatory Compounds in Foodstuff or Medicinal Herbs Inducing Heme Oxygenase-1 Expression. | Antioxidants (Basel) | 2020 | https://conductscience.org/library/papers/33260980 | PubMed |
| 25,869,824 | Topoisomerase I deficiency causes RNA polymerase II accumulation and increases AID abundance in immunoglobulin variable genes. | DNA Repair (Amst) | 2015 | https://conductscience.org/library/papers/25869824 | PubMed |
| 20,526,281 | Topoisomerase I regulates open chromatin and controls gene expression in vivo. | EMBO J | 2010 | https://conductscience.org/library/papers/20526281 | PubMed |
| 18,852,129 | Cisplatin abrogates the geldanamycin-induced heat shock response. | Mol Cancer Ther | 2008 | https://conductscience.org/library/papers/18852129 | PubMed |
| 12,466,531 | Human topoisomerase I cleavage complexes are repaired by a p53-stimulated recombination-like reaction in vitro. | Nucleic Acids Res | 2002 | https://conductscience.org/library/papers/12466531 | PubMed |
| 12,242,659 | The tumor suppressor protein p53 stimulates the formation of the human topoisomerase I double cleavage complex in vitro. | Oncogene | 2002 | https://conductscience.org/library/papers/12242659 | PubMed |
| 11,470,877 | A human topoisomerase I cleavage complex is recognized by an additional human topisomerase I molecule in vitro. | Nucleic Acids Res | 2001 | https://conductscience.org/library/papers/11470877 | PubMed |
| 9,655,174 | Inhibition of DNA topoisomerase I activity by heparan sulfate and modulation by basic fibroblast growth factor. | Mol Cell Biochem | 1998 | https://conductscience.org/library/papers/9655174 | PubMed |
| 9,497,914 | Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas. | Mol Pathol | 1997 | https://conductscience.org/library/papers/9497914 | PubMed |
| 9,328,159 | Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. | Br J Cancer | 1997 | https://conductscience.org/library/papers/9328159 | PubMed |
| 9,321,666 | In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells. | Nucleic Acids Res | 1997 | https://conductscience.org/library/papers/9321666 | PubMed |
| 8,943,335 | Targeted disruption of the mouse topoisomerase I gene by camptothecin selection. | Mol Cell Biol | 1996 | https://conductscience.org/library/papers/8943335 | PubMed |
| 8,265,582 | Identification of human DNA topoisomerase I as a cofactor for activator-dependent transcription by RNA polymerase II. | Proc Natl Acad Sci U S A | 1993 | https://conductscience.org/library/papers/8265582 | PubMed |
| 8,258,194 | Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine. | Cancer Chemother Pharmacol | 1993 | https://conductscience.org/library/papers/8258194 | PubMed |
| 8,127,705 | Activation of cAMP-dependent protein kinase alters the chromatin structure of the urokinase-type plasminogen activator gene promoter. | Nucleic Acids Res | 1994 | https://conductscience.org/library/papers/8127705 | PubMed |
| 7,902,524 | Transcription termination and polyadenylation in retroviruses. | Microbiol Rev | 1993 | https://conductscience.org/library/papers/7902524 | PubMed |
| 7,784,183 | Presence of negative torsional tension in the promoter region of the transcriptionally poised dihydrofolate reductase gene in vivo. | Nucleic Acids Res | 1995 | https://conductscience.org/library/papers/7784183 | PubMed |
| 2,850,477 | Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks. | Mol Cell Biol | 1988 | https://conductscience.org/library/papers/2850477 | PubMed |
| 2,849,758 | Topoisomerase I interaction with SV40 DNA in the presence and absence of camptothecin. | Nucleic Acids Res | 1988 | https://conductscience.org/library/papers/2849758 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2887294
GET https://conductscience.org/api/papers/v1/2887294/cited_by?page=2